AbbVie Inc. (ABBV) — Quantitative Forecast & Factor Scores

ABBV currently carries a valuation grade of Strong Buy. At a trailing P/E of 87.9, the stock trades at a 300% premium to the Healthcare sector median of 22.0x. Our discounted cash flow model suggests an intrinsic range of $227–$404, implying a +51% margin of safety at the current price of $208.34.

With a beta of 0.33, ABBV exhibits a low-volatility risk profile relative to the broad market. Net margins of 6.9% fall below the Healthcare average of 18%, suggesting potential margin pressure. Return on equity of 62.2% indicates highly efficient capital allocation.

The company has beaten estimates in 67% of recent quarters, a moderate hit rate. The most recent quarter delivered a +7.7% earnings surprise. Analyst estimate revisions are trending accelerating.

Insiders have been net sellers to the tune of $108,123,276 recently. While routine dispositions are common, the magnitude bears watching. Short interest is low at 1.2% of float, suggesting limited bearish conviction.

At 0.71, the put/call ratio skews bullish, with call buyers dominating recent flow. Implied volatility of 35.8% exceeds realized volatility of 27.9% by 8 points, suggesting options are pricing in elevated risk.

As a Healthcare constituent, ABBV's risk profile should be evaluated alongside sector peers when constructing diversified portfolios.